« Back to Record
Citation APA

Paternot, S., Raspé, E., Meiller, C., Tarabichi, M., Assié, J.-B., Libert, F., Remmelink, M., Bisteau, X., Pauwels, P., Blum, Y., Le Stang, N., TABONE-EGLINGER, S., Galateau-Salle, F., Blanquart, C., van Meerbeeck, J. P., Berghmans, T., Jean, D., & Roger, P. P. (2022). Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition. Molecular Oncology. doi:https://doi.org/10.1002/1878-0261.13351


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/351709

Paternot, S., Raspé, E., Meiller, C., Tarabichi, M., Assié, J.-B., Libert, F., Remmelink, M., Bisteau, X., Pauwels, P., Blum, Y., Le Stang, N., TABONE-EGLINGER, S., Galateau-Salle, F., Blanquart, C., van Meerbeeck, J. P., Berghmans, T., Jean, D., & Roger, P. P. (2022). Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition. Molecular Oncology. doi:https://doi.org/10.1002/1878-0261.13351